xylometazolin
hydrochlorid
hcl
hcl
wellestablish
nasal
decongest
belong
pharmacotherapeut
group
sympathomimet
drug
act
select
receptor
alphaadrenerg
agonist
xylometazolin
hcl
appli
topic
reliev
nasal
congest
associ
acut
chronic
rhiniti
common
cold
sinus
hay
fever
allergi
caus
vasoconstrict
nasal
submucosa
manifest
collaps
venou
sinusoid
xylometazolin
hcl
action
character
fast
onset
effect
obtain
minut
last
efficaci
xylometazolin
hcl
topic
nasal
decongest
well
xylometazolin
hcl
use
eu
treatment
nasal
congest
caus
rhinitissinus
sinc
sinc
larg
number
prepar
contain
xylometazolin
hcl
approv
market
sever
european
countri
carrageenan
highmolecularweight
sulfat
polym
deriv
red
seawe
rhodophycea
extens
use
food
cosmet
pharmaceut
industri
gener
recogn
safe
gra
us
food
drug
administr
fda
review
cohen
three
main
form
carrageenan
commerci
use
iota
kappa
lambdacarrageenan
differ
degre
sulfat
solubl
gell
antivir
mechan
carrageenan
base
interfer
viral
attach
carrageenan
form
barrier
mucos
surfac
therebi
prevent
interact
viru
cellular
surfac
result
infect
cell
inhibit
antivir
effect
vari
type
polym
well
viru
host
review
alreadi
publish
iotacarrageenan
potent
inhibitor
major
intercellular
adhes
molecul
receptor
minor
group
lowdens
lipoprotein
receptor
human
rhinoviru
hrv
influenza
viru
furthermor
demonstr
broad
antivir
efficaci
iotacarrageenan
contain
nasal
spray
common
cold
virus
sever
random
doubleblind
parallelgroup
placebocontrol
clinic
pool
analysi
two
studi
conduct
children
adult
reveal
patient
infect
respiratori
viru
intranas
treat
iotacarrageenan
show
faster
recoveri
common
cold
symptom
placebotr
patient
intentiontotreat
carrageenan
contain
medic
devic
nasal
spray
approv
market
eu
year
support
treatment
common
coldflulik
ill
caus
virus
rational
merg
xylometazolin
hcl
iotacarrageenan
one
product
base
intent
combin
properti
name
decongest
efficaci
provid
xylometazolin
hcl
effect
reduc
viral
infect
accomplish
iotacarrageenan
intranas
topic
applic
provid
reliabl
fast
relief
symptom
nasal
congest
facilit
breath
common
coldflulik
ill
allerg
rhiniti
furthermor
facilit
drainag
secret
sinus
use
adjuv
treatment
mucos
swell
due
otiti
media
addit
iotacarrageenan
reduc
reproduct
spread
respiratori
virus
describ
indic
frequent
involv
viral
infect
worsen
cours
underli
disesas
therefor
nasal
spray
combin
decongest
antivir
properti
benefiti
patient
compar
convent
xylometazolin
hcl
product
therefor
medicin
product
contain
xylometazolin
hcl
iotacarrageenan
propos
indic
rout
administr
advantag
reason
scientif
medicin
point
view
order
evalu
whether
properti
xylometazolin
hcl
affect
presenc
iotacarrageenan
set
experi
perform
follow
test
solut
tabl
use
experi
describ
method
section
human
cervic
epitheli
carcinoma
cell
line
hela
obtain
american
type
cultur
collect
atcc
manassa
va
usa
cell
cultiv
dulbecco
minim
essenti
medium
sigmaaldrich
vienna
austria
supplement
fetal
bovin
serum
sigmaaldrich
mix
sigmaaldrich
incub
sanyo
okayama
prefectur
japan
rel
humid
viru
infect
viral
experi
medium
contain
fetal
bovin
serum
mix
use
serotyp
obtain
atcc
grown
hela
cell
stock
frozen
viru
titer
determin
tissu
cultur
infect
dose
assay
vero
embryon
african
green
monkey
kidney
cell
purchas
atcc
cell
cultiv
optipro
serumfre
medium
life
technolog
thermo
fisher
scientif
waltham
usa
supplement
mm
lglutamin
sigmaaldrich
incub
rel
humid
hcov
obtain
atcc
propag
medium
stock
frozen
viru
titer
determin
assay
assay
perform
describ
brief
dilut
seri
assay
refer
nacl
prepar
base
formul
nacl
respect
first
viru
preincub
dilut
seri
test
sampl
control
minut
infect
period
minut
cell
wash
cultiv
presenc
test
sampl
concentr
use
viru
preincub
period
incub
cell
dilut
seri
absenc
viral
infect
perform
monitor
potenti
toxic
treatment
antivir
activ
sampl
dilut
assess
hour
cultur
determin
viabil
hela
cell
normal
toxic
data
noninfect
control
highest
iotacarrageenan
dose
maxim
xylometazolin
hcl
concentr
obtain
well
toler
cell
enabl
comparison
antivir
effect
test
solut
half
maxim
inhibitori
concentr
sampl
calcul
sigmoid
model
xlfit
excel
addin
version
assay
perform
describ
brief
viru
preincub
dilut
seri
test
item
minut
room
temperatur
suspens
chicken
red
blood
cell
rbc
ad
incub
hour
plate
photograph
evalu
posit
control
rbc
absenc
test
sampl
fulli
agglutin
viru
wherea
inhibit
hemagglutin
observ
well
contain
suffici
amount
iotacarrageenan
inhibit
viru
bind
rbc
minim
inhibitori
concentr
sampl
maintain
rbc
mobil
note
comparison
antivir
efficaci
sampl
assay
condit
result
compar
refer
sampl
known
inhibitori
activ
prior
use
fertil
egg
lohmann
select
leghorn
schropper
gmbh
vienna
austria
place
motordriven
egg
incub
humidifi
atmospher
start
embryon
develop
embryo
develop
day
edd
egg
rotat
store
blunt
end
edd
ml
albumen
extract
punctur
hole
near
point
end
egg
afterward
seal
molten
wax
cam
access
blunt
end
remov
eggshel
outer
membran
steril
forcep
open
seal
adhes
tape
egg
incub
egg
incub
check
daili
viabil
andor
infect
edd
cam
photograph
minut
minut
applic
test
sampl
digit
imag
use
measur
diamet
blood
vessel
imagej
softwar
studi
perform
thiomatrix
gmbh
innsbruck
austria
test
solut
describ
tabl
tissu
sampl
size
freshli
excis
bovin
respiratori
mucosa
nasal
caviti
obtain
local
slaughterhous
landmetzgerei
piegger
kg
sistran
austria
insert
ussingtyp
chamber
display
permeat
area
apic
side
tissu
therefor
face
donor
compart
preheat
permeat
medium
contain
mm
mm
kcl
mm
nacl
mm
mm
dglucos
mm
hepe
buffer
ph
ad
donor
acceptor
chamber
preincub
time
minut
permeat
medium
donor
chamber
substitut
mixtur
buffer
xylometazolin
hcl
test
sampl
without
iotacarrageenan
fluorescein
isothiocyanatelabel
dextran
kda
sodium
fluorescein
naflu
final
concentr
mv
respect
serv
control
time
period
minut
aliquot
withdrawn
acceptor
compart
everi
minut
immedi
replac
permeat
medium
preheat
concentr
fluoresc
marker
withdrawn
aliquot
determin
alreadi
describ
addit
integr
bovin
nasal
mucosa
proven
transepitheli
electr
resist
measur
studi
test
carri
fivefold
least
statist
data
analysi
perform
use
oneway
anova
follow
test
p
minim
level
signific
local
toler
studi
perform
three
treatment
group
includ
two
dose
group
one
control
group
three
group
compris
three
male
three
femal
new
zealand
white
rabbit
anim
receiv
repeat
applic
test
item
control
left
nostril
untreat
right
nostril
serv
neg
control
dosag
test
item
group
control
group
per
applic
per
day
three
applic
per
day
dosag
formul
contain
iotacarrageenan
per
applic
correspond
daili
dose
xylometazolin
hcl
per
applic
correspond
daili
dose
dosag
contain
amount
xylometazolin
hcl
iotacarrageenan
control
compris
base
formul
describ
tabl
applic
nostril
observ
sign
irrit
edema
reaction
accord
defin
classif
system
draiz
score
nostril
examin
otoscop
begin
treatment
period
day
anim
weigh
prior
first
applic
week
thereaft
clinic
biochemistri
hematolog
paramet
determin
prior
first
treatment
end
treatment
period
end
studi
anim
sacrif
subject
gross
necropsi
wet
weight
set
tissu
taken
set
organstissu
preserv
full
histopatholog
carri
nasal
caviti
includ
turbin
left
right
nostril
brain
includ
bulbu
olfactoriu
medullapon
cerebellar
cerebr
cortex
organ
macroscop
find
studi
anim
statist
assess
perform
sex
compar
valu
treat
control
anim
use
oneway
anova
post
hoc
dunnett
test
statist
perform
graphpad
prism
softwar
eworkbook
softwar
p
studi
perform
test
facil
bsl
bioservic
scientif
laboratori
gmbh
planegg
germani
conduct
complianc
committe
medicin
product
human
use
chmp
note
guidanc
repeat
dose
toxic
corr
juli
effect
inhibit
replic
tabl
test
comparison
nacl
refer
highest
test
iotacarrageenan
concentr
maxim
xylometazolin
hcl
concentr
obtain
still
well
toler
cell
expect
iotacarrageenancontain
solut
show
compar
antivir
effect
shown
valu
overlap
confid
interv
tabl
abil
hcov
agglutin
chicken
erythrocyt
dose
depend
inhibit
iotacarrageenan
util
hai
assay
evalu
antivir
efficaci
iotacarrageenancontain
test
sampl
comparison
refer
sampl
known
inhibitori
activ
describ
test
abil
inhibit
hemagglutin
erythrocyt
hcov
comparison
nacl
refer
descript
test
solut
see
tabl
highest
test
iotacarrageenan
concentr
maxim
xylometazolin
hcl
concentr
obtain
still
well
toler
erythrocyt
iotacarrageenancontain
solut
show
antivir
effect
name
mic
tabl
conclus
confirm
iotacarrageenan
retain
antivir
effect
presenc
xylometazolin
hcl
cam
highli
vascular
membran
surround
develop
chicken
embryo
hetcam
sensit
cheap
easili
feasibl
test
investig
potenti
antiinflammatori
compound
extract
wide
use
assess
irrit
potenti
test
first
describ
accord
origin
test
method
fertil
hen
egg
incub
optim
condit
day
day
egg
open
cam
expos
ml
test
substanc
appli
surfac
cam
defin
exposur
period
cam
evalu
develop
irrit
endpoint
hyperemia
hemorrhag
coagul
effect
cam
blood
vessel
albumen
subject
assess
score
sever
altern
paramet
like
lysi
hyperemia
vasoconstrict
evalu
use
adapt
hetcam
use
adapt
hetcam
protocol
test
vasoconstrict
potenti
xylometazolin
hcl
presenc
absenc
iotacarrageenan
cam
photograph
minut
applic
test
sampl
shown
tabl
vasoconstrict
effect
combin
product
reduct
initi
vessel
diamet
compar
effect
singl
compound
reduct
initi
vessel
diamet
overlap
confid
interv
mean
diamet
sampl
indic
differ
signific
vasoconstrict
mediat
xylometazolin
hcl
preserv
presenc
iotacarrageenan
ex
vivo
mucos
permeat
studi
perform
investig
impact
iotacarrageenan
permeat
abil
xylometazolin
hcl
end
permeat
xylometazolin
hcl
presenc
absenc
iotacarrageenan
evalu
freshli
excis
bovin
nasal
mucosa
naflu
use
posit
control
fluoresceinlabel
dextran
molecular
mass
kda
use
neg
control
result
permeat
experi
tabl
display
compar
high
permeat
naflu
contrast
pass
nasal
mucosa
furthermor
within
hour
permeat
determin
comparison
xylometazolin
hcl
without
iotacarrageenan
permeat
tissu
indic
transport
xylometazolin
hcl
significantli
impair
presenc
iotacarrageen
shown
overlap
confid
interv
conduct
local
toler
toxic
studi
compar
base
formul
control
tabl
purpos
studi
obtain
inform
toler
rabbit
repeat
administr
period
day
appli
three
timesday
doseappl
xylometazolin
hcl
iotacarrageenan
applic
deliv
dose
xylometazolin
hcl
iotacarrageenan
mortal
occur
control
dose
group
treatment
period
studi
threetim
daili
administr
neither
associ
clinic
symptom
male
femal
rabbit
applic
site
test
solut
well
toler
throughout
studi
neither
erythema
edema
observ
nostril
anim
effect
bodi
weight
hematolog
paramet
treatmentrel
effect
clinic
biochemistri
assum
treatment
chang
singl
paramet
eg
alanineaminotransferas
aspartateaminotransferas
glutam
dehydrogenas
observ
singl
anim
treat
howev
chang
sever
consid
toxicolog
relev
compar
minimummaximum
rang
control
histor
data
andor
pretreat
valu
addit
correl
paramet
eg
histopatholog
determin
aforement
find
gross
patholog
abnorm
abnorm
organ
weight
toxicolog
concern
found
anim
treat
treatment
slightli
higher
thymu
epididymid
prostat
ovari
weight
found
slightli
significantli
higher
weight
thymu
spleen
ovari
epididymid
also
associ
treatment
howev
rel
organ
weight
exceed
valu
respect
histor
control
conclus
well
toler
applic
site
occurr
erythema
edema
nostril
anim
sign
toxic
daili
dose
test
produc
morpholog
indic
toxic
organ
tissu
examin
test
itemrel
chang
clinic
biochemistri
paramet
rel
organ
weight
detect
studi
carrageenan
extens
use
food
cosmet
pharmaceut
industri
fda
list
gener
recogn
safe
gra
product
consumpt
cfr
demonstr
antivir
effect
iotacarrageenan
varieti
respiratori
virus
sever
preclin
clinic
trial
therefor
approv
market
eu
asia
australia
part
varieti
overthecount
product
address
common
cold
relat
diseas
iotacarrageenan
effect
wide
rang
virus
envelop
herp
simplex
virus
human
cytomegaloviru
vesicular
stomat
viru
sindbi
viru
influenza
viru
human
immunodefici
nonenvelop
human
one
vast
number
differ
viral
cellular
receptor
molecul
involv
infect
rule
specif
interact
iotacarrageenan
viral
attach
protein
demonstr
mode
action
unspecif
sole
physic
base
consider
propos
antivir
activ
carrageenan
base
twostepmechan
first
iotacarrageenan
form
viscou
layer
mucosa
viru
particl
enter
nasal
caviti
becom
trap
therefor
infect
mucos
cell
primari
infect
prevent
second
newli
synthes
viru
particl
excret
cell
adher
carrageenan
film
well
result
inhibit
secondari
infect
lead
signific
reduct
viral
load
nasal
fluid
henc
reduct
durat
mechanist
scenario
support
permeat
experi
describ
hebar
et
permeat
behavior
methyl
anthranoyllabel
iotacarrageenan
bovin
nasal
mucosa
evalu
ph
healthi
nasal
mucosa
ph
infect
nasal
mucosa
permeat
observ
ph
valu
period
hour
indic
carrageenan
still
present
surfac
film
want
know
long
carrageenan
stay
nasal
mucosa
remov
mucociliari
clearanc
system
end
perform
adapt
saccharin
test
first
describ
andersen
et
evalu
time
tast
clearanc
presenc
absenc
iotacarrageenan
conduct
crossov
studi
nasal
mucociliari
clearanc
nmc
time
determin
healthi
volunt
femal
male
age
year
doubl
blind
setup
end
two
nasal
spray
formul
contain
glycyrrhizin
tast
marker
without
iotacarrageenan
prepar
blind
test
formul
appli
nostril
time
applic
first
detect
tast
time
absenc
tast
note
data
nmc
mean
valu
sd
calcul
group
mean
nmc
time
minut
carrageenanfre
group
carrageenan
present
nmc
extend
minut
data
conclud
carrageenan
form
protect
layer
mucosa
stay
hour
time
mucosa
protect
viral
infect
importantli
result
present
paper
demonstr
carrageenan
barrier
influenc
permeat
behavior
toxic
safeti
profil
vasoconstrict
efficaci
xylometazolin
hcl
antivir
effect
remain
unchang
nasal
spray
contain
xylometazolin
hcl
iotacarrageenan
treatment
adjuv
treatment
common
cold
sinus
rhiniti
otiti
media
advantag
reason
scientif
medicin
point
view
investig
compat
xylometazolin
hcl
iotacarrageenan
demonstr
iotacarrageenan
impair
efficaci
safeti
xylometazolin
hcl
vice
versa
